Which company develops and produces Venacla?

Venetoclax is developed and produced by AbbVie Biopharmaceuticals in the United States. Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration in April 2016. Veneclat is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Veneclat is also indicated in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of adults 75 years of age or older with newly diagnosed acute myeloid leukemia (AML) or with comorbidities that preclude intensive induction chemotherapy.

Venetoclatis highly bound to human plasma proteins, and in the concentration range of1-30m (0.87-26g/mL), in vitro studies have shown that venetoclat is mainly metabolized as a substrate for CYP3A4/5. Single oral administration to healthy subjects200 mgRadiolabeled [14C]Veneclasedose, 9dose found in feces》 99.9%, and the urine dose 0.1%, suggesting that hepatic clearance is responsible for veneclat's removal from the systemic circulation. Unaltered toxins accounted for 20.8% of the radioactive dose excreted in feces. The reported half-life of veneclase is 19-26 hours following a single 50 mg dose. Venexaclav may cause harm to the embryo when taken by pregnant women. Patients should avoid becoming pregnant during treatment. Based on testicular toxicity (germ cell loss) results observed in dogs, there is a risk to human male fertility at doses as low as 0.5 times the recommended AUC exposure. The retail price of generic venetoclax 100mg120 tablets ranges from 2 to more than 6 more than 1,000. If you want to get more high-quality information, you can contact YaoDe,Yaidewill do its best to learn more about high-quality overseas drugs for you.